A Phase 2 interventional study of M2591 25 mg QD and M2951 75 mg QD in Rheumatoid Arthritis, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 98 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-28.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 290 studies in Arthritis, Rheumatoid with a site in Poland — 13 open to participants now, 22 under way, 3 of them phase 3. Arthritis, Rheumatoid · Poland.
Among the 290 studies in Arthritis, Rheumatoid with a site in Poland, this one is the 112th largest by enrollment of the 284 interventional ones that give a count, is one of 11 that started in 2017, is one of 141 in phase 2, and was the 229th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →13 of the 290 studies in Arthritis, Rheumatoid with a site in Poland are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Poland, United States, Belgium and 8 more countries
Ages 18–65
Hoffmann-La Roche · Sites in Poland, United States, Brazil
Ages 18+
4th Military Clinical Hospital with Polyclinic, Poland · Sites in Poland
Ages 18+
GlaxoSmithKline · Sites in Poland, Argentina, Brazil and 6 more countries
Ages 18–70
AstraZeneca · Sites in Poland, United States, Argentina and 14 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
290 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 149 · Phase 3 106 · Phase 4 10
First in 2001; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 390 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 292 across the 284 interventional studies, 193 across the 6 observational. Of the 267 that completed or were terminated, 196 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
285 of 290 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
Merck KGaA, Darmstadt, Germany has 7 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
6 of the studies in Arthritis, Rheumatoid with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT06754462Immunovant Sciences GmbHA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 290 studies in Arthritis, Rheumatoid with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: M2591 25 mg QD
Drug: M2951 75 mg QD
Drug: M2951 50 mg BID
Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
Also known as: Evobrutinib
Participants received 75 mg of M2951 orally QD for 12 weeks.
Also known as: Evobrutinib
Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
Also known as: Evobrutinib
Participants received placebo matched to M2951 orally for 12 weeks.
Percentage of Participants Who Achieved American College of Rheumatology 20 Percent (%) Response Criteria (ACR20) Assessed Using High-Sensitivity C-reactive Protein (hsCRP) at Week 12
ACR20 response: a participant has at least 20% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Percentage of participants with ACR20 response using hsCRP = Number of participants with ACR20 response using hsCRP divided by total modified intent-to-treat (mITT) participants \* 100.
Time frame: Week 12
Percentage of Participants With Low Disease Activity Score (DAS28 Less Than [<] 3.2) Based on 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12
Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28) + 0.36\*natural log(hsCRP+1) + 0.014\* participant's global assessment of disease activity + 0.96. Scores ranged 0-9.4, where lower scores indicated less disease activity. Percentage of participants with low DAS28 \< 3.2 based on DAS28- hsCRP at Week 12 were reported.
Time frame: Week 12
Percentage of Participants With Remission Disease Activity Score (DAS28 Less Than [<] 2.6) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12
Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28) + 0.36\*natural log(hsCRP+1) + 0.014\* participant's global assessment of disease activity + 0.96. Scores ranged 0-9.4, where lower scores indicated less disease activity. A DAS28 score less than (\<) 2.6 indicated clinical remission. Percentage of participants with low DAS28 \< 2.6 based on DAS28- hsCRP at Week 12 were reported.
Time frame: Week 12
Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50)
ACR50 response: a participant has at least 50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 50% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\]; and 5) acute phase reactant as measured by High-sensitivity C-reactive protein \[hsCRP\]. Percentage of participants with ACR50 response = Number of participants with ACR50 response divided by total mITT participants \* 100.
Time frame: Week 12
Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70)
ACR70 response: a participant has at least 70% improvement ACR70 response in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 70% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\]; and 5) acute phase reactant as measured by High-sensitivity C-reactive protein \[hsCRP\]. Percentage of participants with ACR70 response = Number of participants with ACR70 response divided by total mITT participants \* 100.
Time frame: Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inparticipant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 16 weeks. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.
Time frame: up to Week 16
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported.
Time frame: up to Week 16
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.
Time frame: up to Week 16
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.
Time frame: up to Week 16
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings
12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.
Time frame: up to Week 16
Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2, 4, 8, 12 and 16
Change in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline, Week 2, 4, 8, 12 and 16
Change From Baseline in B Cell Count at Week 2, 4, 8, 12 and 16
Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
Time frame: Baseline, Week 2, 4, 8, 12 and 16
Percentage of Participants With Remission Assessed by American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean at Week 12
ACR-EULAR Boolean remission was when a participant satisfied all of the following: tender joint count, swollen joint count (both based on a 28-joint assessment), C-reactive Protein (in milligrams per deciliter \[mg/dL\]), and participant's global assessment (visual analog scale \[VAS\]: 0 centimeter (cm) \[very well\] to 10 cm \[worst\], higher scores indicated worse health condition) and all scores were less than or equal to (\<=) 1. Percentage of participants with ACR-EULAR Boolean Remission were reported.
Time frame: Week 12
Percentage of Participants With Clinical Disease Activity Index (CDAI) Score Less Than or Equal to [=<] 2.8 at Week 12
CDAI: a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PhGA where, GH = general health component of the Disease Activity Score \[DAS\] (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total CDAI score ranges from 0 to 76, where 0 (none) to 76 (extreme disease activity). CDAI score =\< 2.8 indicated clinical remission. Percentage of participants with CDAI score =\< 2.8 were reported.
Time frame: Week 12
Percentage of Participants With Simplified Disease Activity Index (SDAI) Score Less Than or Equal to [=<] 3.3 at Week 12
SDAI was calculated based on following formula: SDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA + hsCRP where, GH = general health component of the Disease Activity Score \[DAS\] (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total SDAI score ranges from 0 to 86, where 0 (none) to 86 (extreme disease activity). SDAI score =\< 3.3 indicated clinical remission. Percentage of participants with SDAI score =\< 3.3 at Week 12 were reported.
Time frame: Week 12
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 12
EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP scores range from 0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP \<3.2, and remission: DAS28-CRP \<2.6. EULAR DAS28-CRP responder index: good (absolute: \<3.2 or \>1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: \>5.1 or \<0.6 improvement from baseline). Percentage of Participants With Good or Moderate EULAR Responses were reported.
Time frame: Week 12
American College of Rheumatology (ACR) Hybrid Scores Computed Using High-Sensitivity C-reactive Protein (hsCRP)
The hybrid ACR combines the ACR 20/50/70 response with the mean percent change in all 7 ACR core components, thus providing a percent improvement from baseline on a continuous scale. For each participant, the mean percent improvement from baseline across the 7 ACR core set measures (tender joint count, swollen joint count, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, disability index of the Health Assessment Questionnaire \[HAQ\], and C-reactive protein \[CRP\]) was calculated (a positive change indicated improvement, and the maximum worst change was limited to -100%) and the ACR20, ACR50, and ACR70 response is determined. The hybrid ACR is determined from a reference table taking into account both ACR response and mean percent improvement in the core set measures. Scores can range from -100% (maximal worsening) to 100% (maximal improvement).
Time frame: Baseline, Week 12
Change From Baseline in Disease Activity Score (DAS) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12
DAS28 was a composite score used for measuring disease activity in participants with rheumatoid arthritis. The calculation was based on the tender joint count (out of 28 joints), swollen joint count (out of 28 joints), hsCRP (milligrams per liter \[mg/L\]) and Participant's Global Assessment of Disease Activity. Total DAS28-hsCRP score ranged from 0 (none) to 9.4 (extreme disease activity). DAS28-hsCRP \< 3.2 implied low disease activity and \>= 3.2 to \<= 5.1 implied moderate disease activity, \> 5.1 implied high disease activity. DAS28-hsCRP = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(hsCRP in mg/L +1) + 0.014\* Participant's Global Assessment of Disease Activity + 0.96; ln = natural logarithm, sqrt = square root.
Time frame: Baseline, Week 12
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12
The CDAI was a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PhGA where, GH = general health component of the DAS (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total CDAI score ranges from 0 to 76, where 0 (none) to 76 (extreme disease activity).
Time frame: Baseline, Week 12
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12
SDAI was numerical sum of 5 outcome parameters: 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA + hsCRP where, GH = general health component of the DAS (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total SDAI score ranges from 0 to 86, where 0 (none) to 86 (extreme disease activity).
Time frame: Baseline, Week 12
Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12
Sixty-eight joints were assessed and classified as tender/not tender and Sixty-six joints were classified as swollen/not swollen by pressure and joint manipulation on physical examination.
Time frame: Baseline, Week 12
Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12
The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).
Time frame: Baseline, Week 12
Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12
The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.
Time frame: Baseline, Week 12
Changes From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12
HAQ-DI score was an evaluation of the functional status for a participant. The 20-question instrument assessed the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0, indicated no difficulty, to 3, indicated inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Week 12
Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12
The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).
Time frame: Baseline, Week 12
Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12
hsCRP was the American College of Rheumatology (ACR) Core Set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of M2951 on the participant's rheumatoid arthritis.
Time frame: Baseline, Week 12
Percent Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12
Sixty-eight joints were assessed and classified as tender/not tender and Sixty-six joints were classified as swollen/not swollen by pressure and joint manipulation on physical examination.
Time frame: Baseline, Week 12
Percent Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12
The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).
Time frame: Baseline, Week 12
Percent Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12
The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.
Time frame: Baseline, Week 12
Percent Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12
HAQ-DI score was an evaluation of the functional status for a participant. The 20-question instrument assessed the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0, indicated no difficulty, to 3, indicated inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Week 12
Percent Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12
The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).
Time frame: Baseline, Week 12
Percent Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12
hsCRP was the American College of Rheumatology (ACR) Core Set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of M2951 on the participant's rheumatoid arthritis.
Time frame: Baseline, Week 12
Change From Baseline in Synovitis Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12
A total of 8 joints in the hand and wrist were evaluated for RAMRIS synovitis. Individual joint scores were assessed on a scale of 0 (no synovitis) to 3 (67 to 100 percent volume enhancement). The final synovitis score was the sum of the individual joint scores. The total score from 8 joints ranges from 0 to 24, with 0 implying normal (no synovitis) and 24 implying 67 to 100 percent volume enhancement.
Time frame: Baseline, Week 12
Change From Baseline in Bone Marrow Edema (Osteitis) Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12
A total of 25 locations in the hand and wrist were evaluated for RAMRIS bone edema or osteitis. Individual location scores range from 0 (no edema) to 3 (67 to 100 percent involvement of original articular bone) based on the proportion of estimated originally non-eroded bone involved. The final bone edema or osteitis score is the sum of the individual location scores. The total score from the 25 locations ranges from 0 to 75, with 0 implying no bone edema or osteitis and 75 implying 67 to 100 percent involvement of original articular bone.
Time frame: Baseline, Week 12
Change From Baseline in Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12
The HAQ-DI questionnaire assessed the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Time frame: Baseline, Week 12
Change From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score at Week 12
The 36-Item Short-Form Health Survey (SF-36) was a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) was based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100 = highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100 = highest level of physical functioning).
Time frame: Baseline, Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assess self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.
Time frame: Baseline, Week 12
| Milestone | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Started | 97 | 98 | 96 | 99 |
| Completed | 82 | 83 | 84 | 91 |
| Not completed | 15 | 15 | 12 | 8 |
| Withdrew: Adverse event | 6 | 3 | 6 | 3 |
| Withdrew: Protocol violation | 1 | 2 | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Other | 5 | 5 | 5 | 3 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 0 |
ACR20 response: a participant has at least 20% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Percentage of participants with ACR20 response using hsCRP = Number of participants with ACR20 response using hsCRP divided by total modified intent-to-treat (mITT) participants \* 100.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants Who Achieved American College of Rheumatology 20 Percent (%) Response Criteria (ACR20) Assessed Using High-Sensitivity C-reactive Protein (hsCRP) at Week 12 | 49.5 | 59.2 | 51.0 | 59.6 |
Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28) + 0.36\*natural log(hsCRP+1) + 0.014\* participant's global assessment of disease activity + 0.96. Scores ranged 0-9.4, where lower scores indicated less disease activity. Percentage of participants with low DAS28 \< 3.2 based on DAS28- hsCRP at Week 12 were reported.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Low Disease Activity Score (DAS28 Less Than [<] 3.2) Based on 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12 | 7.2 | 20.4 | 24.0 | 20.2 |
Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28) + 0.36\*natural log(hsCRP+1) + 0.014\* participant's global assessment of disease activity + 0.96. Scores ranged 0-9.4, where lower scores indicated less disease activity. A DAS28 score less than (\<) 2.6 indicated clinical remission. Percentage of participants with low DAS28 \< 2.6 based on DAS28- hsCRP at Week 12 were reported.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Remission Disease Activity Score (DAS28 Less Than [<] 2.6) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12 | 1.0 | 10.2 | 10.4 | 10.1 |
ACR50 response: a participant has at least 50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 50% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\]; and 5) acute phase reactant as measured by High-sensitivity C-reactive protein \[hsCRP\]. Percentage of participants with ACR50 response = Number of participants with ACR50 response divided by total mITT participants \* 100.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) | 19.6 | 28.6 | 27.1 | 26.3 |
ACR70 response: a participant has at least 70% improvement ACR70 response in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 70% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\]; and 5) acute phase reactant as measured by High-sensitivity C-reactive protein \[hsCRP\]. Percentage of participants with ACR70 response = Number of participants with ACR70 response divided by total mITT participants \* 100.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) | 5.2 | 11.2 | 10.4 | 10.1 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inparticipant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 16 weeks. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.
| Participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| TEAEs | 44 | 48 | 48 | 50 |
| Serious TEAEs | 2 | 2 | 2 | 1 |
Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported.
| Participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Grade 1 | 33 | 42 | 37 | 40 |
| Grade 2 | 19 | 14 | 23 | 17 |
| Grade 3 | 2 | 5 | 1 | 1 |
| Grade 4 | 0 | 1 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 |
Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.
| Participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 | 0 |
Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.
| Participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters | 0 | 0 | 0 | 0 |
12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.
| Participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 |
Change in the serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| IgG: Week 2 | -0.02 ± 1.083 | -0.07 ± 1.042 | -0.21 ± 0.968 | -0.09 ± 1.062 |
| IgG: Week 4 | -0.05 ± 1.465 | -0.15 ± 1.576 | -0.34 ± 1.254 | -0.17 ± 1.168 |
| IgG: Week 8 | 0.12 ± 1.513 | -0.28 ± 2.052 | -0.37 ± 1.565 | -0.35 ± 2.037 |
| IgG: Week 12 | 0.47 ± 1.617 | -0.17 ± 2.080 | -0.33 ± 1.493 | -0.23 ± 1.781 |
| IgG: Week 16 | 0.08 ± 1.829 | -0.14 ± 2.349 | -0.14 ± 1.808 | 0.06 ± 1.960 |
| IgA: Week 2 | -0.01 ± 0.253 | -0.15 ± 1.187 | 0.00 ± 0.242 | 0.03 ± 0.369 |
| IgA: Week 4 | -0.05 ± 0.326 | -0.01 ± 0.359 | -0.05 ± 0.333 | 0.02 ± 0.396 |
| IgA: Week 8 | -0.02 ± 0.346 | -0.16 ± 1.322 | -0.06 ± 0.373 | 0.07 ± 0.567 |
| IgA: Week 12 | 0.02 ± 0.373 | 0.01 ± 0.444 | -0.08 ± 0.388 | 0.05 ± 0.545 |
| IgA: Week 16 | 0.01 ± 0.466 | 0.07 ± 0.465 | -0.11 ± 0.380 | 0.05 ± 0.478 |
| IgM: Week 2 | -0.04 ± 0.198 | -0.04 ± 0.183 | -0.03 ± 0.281 | -0.01 ± 0.323 |
| IgM: Week 4 | -0.04 ± 0.199 | -0.11 ± 0.224 | -0.11 ± 0.217 | -0.05 ± 0.385 |
| IgM: Week 8 | -0.03 ± 0.310 | -0.20 ± 0.243 | -0.23 ± 0.327 | -0.10 ± 0.485 |
| IgM: Week 12 | -0.01 ± 0.265 | -0.20 ± 0.309 | -0.25 ± 0.296 | -0.17 ± 0.406 |
| IgM: Week 16 | -0.16 ± 0.776 | -0.12 ± 0.436 | -0.22 ± 0.246 | -0.12 ± 0.487 |
Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
| cells per microliter (cells/microliter) | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Week 2 | -13 ± 111.0 | 264 ± 1832.7 | 161 ± 648.3 | 74 ± 144.8 |
| Week 4 | -20 ± 115.7 | 71 ± 130.1 | 66 ± 145.3 | 93 ± 137.6 |
| Week 8 | -21 ± 87.5 | 35 ± 103.1 | 56 ± 188.1 | 59 ± 145.4 |
| Week 12 | -22 ± 136.4 | 41 ± 111.8 | 51 ± 156.2 | 54 ± 145.0 |
| Week 16 | -20 ± 121.9 | -3 ± 108.5 | -40 ± 133.5 | -19 ± 235.6 |
ACR-EULAR Boolean remission was when a participant satisfied all of the following: tender joint count, swollen joint count (both based on a 28-joint assessment), C-reactive Protein (in milligrams per deciliter \[mg/dL\]), and participant's global assessment (visual analog scale \[VAS\]: 0 centimeter (cm) \[very well\] to 10 cm \[worst\], higher scores indicated worse health condition) and all scores were less than or equal to (\<=) 1. Percentage of participants with ACR-EULAR Boolean Remission were reported.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Remission Assessed by American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean at Week 12 | 0.0 | 0.0 | 1.0 | 3.0 |
CDAI: a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PhGA where, GH = general health component of the Disease Activity Score \[DAS\] (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total CDAI score ranges from 0 to 76, where 0 (none) to 76 (extreme disease activity). CDAI score =\< 2.8 indicated clinical remission. Percentage of participants with CDAI score =\< 2.8 were reported.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Clinical Disease Activity Index (CDAI) Score Less Than or Equal to [=<] 2.8 at Week 12 | 1.0 | 4.1 | 6.3 | 3.0 |
SDAI was calculated based on following formula: SDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA + hsCRP where, GH = general health component of the Disease Activity Score \[DAS\] (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total SDAI score ranges from 0 to 86, where 0 (none) to 86 (extreme disease activity). SDAI score =\< 3.3 indicated clinical remission. Percentage of participants with SDAI score =\< 3.3 at Week 12 were reported.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Simplified Disease Activity Index (SDAI) Score Less Than or Equal to [=<] 3.3 at Week 12 | 0.0 | 3.1 | 4.2 | 3.0 |
EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP scores range from 0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP \<3.2, and remission: DAS28-CRP \<2.6. EULAR DAS28-CRP responder index: good (absolute: \<3.2 or \>1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: \>5.1 or \<0.6 improvement from baseline). Percentage of Participants With Good or Moderate EULAR Responses were reported.
| percentage of participants | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 12 | 54.6 | 65.3 | 66.7 | 71.7 |
The hybrid ACR combines the ACR 20/50/70 response with the mean percent change in all 7 ACR core components, thus providing a percent improvement from baseline on a continuous scale. For each participant, the mean percent improvement from baseline across the 7 ACR core set measures (tender joint count, swollen joint count, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, disability index of the Health Assessment Questionnaire \[HAQ\], and C-reactive protein \[CRP\]) was calculated (a positive change indicated improvement, and the maximum worst change was limited to -100%) and the ACR20, ACR50, and ACR70 response is determined. The hybrid ACR is determined from a reference table taking into account both ACR response and mean percent improvement in the core set measures. Scores can range from -100% (maximal worsening) to 100% (maximal improvement).
| percent change | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| American College of Rheumatology (ACR) Hybrid Scores Computed Using High-Sensitivity C-reactive Protein (hsCRP) | 26.51 ± 25.779 | 34.66 ± 29.033 | 33.09 ± 27.724 | 36.99 ± 26.241 |
DAS28 was a composite score used for measuring disease activity in participants with rheumatoid arthritis. The calculation was based on the tender joint count (out of 28 joints), swollen joint count (out of 28 joints), hsCRP (milligrams per liter \[mg/L\]) and Participant's Global Assessment of Disease Activity. Total DAS28-hsCRP score ranged from 0 (none) to 9.4 (extreme disease activity). DAS28-hsCRP \< 3.2 implied low disease activity and \>= 3.2 to \<= 5.1 implied moderate disease activity, \> 5.1 implied high disease activity. DAS28-hsCRP = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(hsCRP in mg/L +1) + 0.014\* Participant's Global Assessment of Disease Activity + 0.96; ln = natural logarithm, sqrt = square root.
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Disease Activity Score (DAS) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12 | -1.21 ± 1.048 | -1.45 ± 1.230 | -1.62 ± 1.257 | -1.75 ± 1.229 |
The CDAI was a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PhGA where, GH = general health component of the DAS (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total CDAI score ranges from 0 to 76, where 0 (none) to 76 (extreme disease activity).
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12 | -16.9 ± 13.09 | -18.0 ± 13.00 | -18.9 ± 14.33 | -20.3 ± 13.90 |
SDAI was numerical sum of 5 outcome parameters: 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA + hsCRP where, GH = general health component of the DAS (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total SDAI score ranges from 0 to 86, where 0 (none) to 86 (extreme disease activity).
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12 | -17.000 ± 13.5175 | -18.647 ± 13.5957 | -19.404 ± 14.1591 | -21.053 ± 14.3720 |
Sixty-eight joints were assessed and classified as tender/not tender and Sixty-six joints were classified as swollen/not swollen by pressure and joint manipulation on physical examination.
| joints | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| TJC | -11 ± 12.0 | -11 ± 10.6 | -13 ± 13.2 | -12 ± 10.8 |
| SJC | -7 ± 7.5 | -8 ± 6.1 | -8 ± 7.7 | -8 ± 6.6 |
The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).
| millimeter (mm) | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12 | -20 ± 29.6 | -19 ± 27.9 | -17 ± 29.6 | -25 ± 25.7 |
The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.
| millimeter | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12 | -21 ± 24.7 | -24 ± 26.9 | -22 ± 24.7 | -25 ± 26.6 |
HAQ-DI score was an evaluation of the functional status for a participant. The 20-question instrument assessed the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0, indicated no difficulty, to 3, indicated inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Changes From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12 | -0.38 ± 0.567 | -0.58 ± 0.662 | -0.40 ± 0.658 | -0.52 ± 0.616 |
The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).
| millimeter | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12 | -29 ± 21.2 | -33 ± 26.5 | -34 ± 26.1 | -37 ± 25.3 |
hsCRP was the American College of Rheumatology (ACR) Core Set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of M2951 on the participant's rheumatoid arthritis.
| milligram per liter (mg/L) | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12 | -1.11 ± 25.925 | -6.42 ± 23.280 | -5.45 ± 28.807 | -7.69 ± 23.007 |
Sixty-eight joints were assessed and classified as tender/not tender and Sixty-six joints were classified as swollen/not swollen by pressure and joint manipulation on physical examination.
| percent change | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| TJC | -39 ± 45.6 | -46 ± 44.2 | -51 ± 42.8 | -49 ± 37.5 |
| SJC | -46 ± 52.7 | -53 ± 42.6 | -56 ± 40.3 | -58 ± 43.8 |
The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).
| percent change | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12 | -13 ± 111.0 | -21 ± 69.3 | -13 ± 65.7 | -33 ± 35.9 |
The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.
| percent change | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12 | -23 ± 65.0 | -32 ± 38.4 | -29 ± 40.5 | -32 ± 48.4 |
HAQ-DI score was an evaluation of the functional status for a participant. The 20-question instrument assessed the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0, indicated no difficulty, to 3, indicated inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| percent change | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12 | -20.09 ± 40.084 | -31.85 ± 37.124 | -21.27 ± 44.571 | -27.12 ± 42.624 |
The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).
| percent change | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12 | -42 ± 31.4 | -44 ± 51.9 | -47 ± 34.9 | -52 ± 33.5 |
hsCRP was the American College of Rheumatology (ACR) Core Set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of M2951 on the participant's rheumatoid arthritis.
| percent change | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12 | 95.01 ± 380.161 | 10.93 ± 167.257 | 182.57 ± 1775.154 | -13.91 ± 105.688 |
A total of 8 joints in the hand and wrist were evaluated for RAMRIS synovitis. Individual joint scores were assessed on a scale of 0 (no synovitis) to 3 (67 to 100 percent volume enhancement). The final synovitis score was the sum of the individual joint scores. The total score from 8 joints ranges from 0 to 24, with 0 implying normal (no synovitis) and 24 implying 67 to 100 percent volume enhancement.
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Synovitis Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12 | 0 ± 1.9 | -1 ± 2.5 | -1 ± 3.4 | -1 ± 2.4 |
A total of 25 locations in the hand and wrist were evaluated for RAMRIS bone edema or osteitis. Individual location scores range from 0 (no edema) to 3 (67 to 100 percent involvement of original articular bone) based on the proportion of estimated originally non-eroded bone involved. The final bone edema or osteitis score is the sum of the individual location scores. The total score from the 25 locations ranges from 0 to 75, with 0 implying no bone edema or osteitis and 75 implying 67 to 100 percent involvement of original articular bone.
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Bone Marrow Edema (Osteitis) Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12 | -1 ± 5.8 | 0 ± 4.6 | 0 ± 5.4 | 0 ± 4.0 |
The HAQ-DI questionnaire assessed the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12 | -0.41 ± 0.543 | -0.61 ± 0.637 | -0.45 ± 0.657 | -0.53 ± 0.631 |
The 36-Item Short-Form Health Survey (SF-36) was a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) was based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100 = highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100 = highest level of physical functioning).
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| PCS | 5.9 ± 7.10 | 7.1 ± 8.50 | 6.4 ± 8.50 | 7.1 ± 8.28 |
| MCS | 4.9 ± 11.46 | 5.7 ± 8.41 | 5.0 ± 11.72 | 4.7 ± 8.95 |
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assess self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.
| units on a scale | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12 | 9 ± 11.4 | 10 ± 9.4 | 9 ± 9.0 | 8 ± 10.7 |
Collected over up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/97 (0%) | 2/97 (2.1%) | 11/97 (11.3%) |
| M2951 25 mg QD | 0/98 (0%) | 2/98 (2%) | 13/98 (13.3%) |
| M2951 75 mg QD | 0/96 (0%) | 2/96 (2.1%) | 8/96 (8.3%) |
| M2951 50 mg BID | 0/99 (0%) | 1/99 (1%) | 17/99 (17.2%) |
| Event | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| OsteomyelitisInfections and infestations | 0/97 | 0/98 | 1/96 | 0/99 |
| Tibia fractureInjury, poisoning and procedural complications | 0/97 | 0/98 | 1/96 | 0/99 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/97 | 0/98 | 0/96 | 0/99 |
| Thrombophlebitis superficialVascular disorders | 1/97 | 0/98 | 0/96 | 0/99 |
| HypersensitivityImmune system disorders | 0/97 | 1/98 | 0/96 | 0/99 |
| SinusitisInfections and infestations | 0/97 | 1/98 | 0/96 | 0/99 |
| LymphoedemaVascular disorders | 0/97 | 1/98 | 0/96 | 0/99 |
| HepatotoxicityHepatobiliary disorders | 0/97 | 0/98 | 0/96 | 1/99 |
| Event | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/97 | 6/98 | 5/96 | 8/99 |
| AnaemiaBlood and lymphatic system disorders | 6/97 | 2/98 | 3/96 | 7/99 |
| DyslipidaemiaMetabolism and nutrition disorders | 0/97 | 5/98 | 0/96 | 2/99 |
The modified intent-to-treat (mITT) analysis set included all randomized participants who received at least one dose of Investigational Medicinal Product (IMP) (M2951 or placebo).
| Age, Continuous(years) | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 52.9 ± 12.24 | 50.9 ± 13.15 | 53.3 ± 11.33 | 53.7 ± 12.13 | 52.7 ± 12.21 |
| Sex: Female, Male(Participants) | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID | Total |
|---|---|---|---|---|---|
| Female | 77 | 82 | 76 | 77 | 312 |
| Male | 20 | 16 | 20 | 22 | 78 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 32 | 33 | 35 | 38 | 138 |
| Not Hispanic or Latino | 65 | 65 | 61 | 61 | 252 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | M2951 25 mg QD | M2951 75 mg QD | M2951 50 mg BID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 0 | 0 | 3 |
| White | 92 | 94 | 91 | 97 | 374 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 4 | 2 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html
Ran from Sep 2017 to primary completion in Sep 2019, 24 months.
Results were first posted in Sep 2020, 1 year after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 24 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
EMD Serono Research & Development Institute, Inc. →